Biohaven Reports Second Quarter 2021 Financial Results And Recent Business Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
UBS Downgrades Biohaven Pharmaceutical Holding (BHVN) to Neutral
August 10, 2021 7:01 AM EDTUBS analyst Esther Rajavelu downgraded Biohaven Pharmaceutical Holding (NYSE: BHVN) from Buy to Neutral with a price target of $109.00 (from $108.00).
The analyst comments "We are moving to Neutral from Buy following a strong 1H21 stock performance for BHVN, primarily driven by Nurtec... More
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $140 at Cowen
August 9, 2021 10:49 AM EDTCowen analyst Ken Cacciatore raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $140.00 (from $130.00) while maintaining an Outperform rating.
The analyst commented, "The Q2 performance validates our and our consultants initial views of the product and depth of need, and it... More
Biohaven Pharma (BHVN) Misses Q2 EPS by 49c
August 9, 2021 7:13 AM EDTBiohaven Pharma (NYSE: BHVN) reported Q2 EPS of ($3.23), $0.49 worse than the analyst estimate of ($2.74). Revenue for the quarter came in at $92.93 million versus the consensus estimate of $78.13 million.
For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.
... More